<DOC>
	<DOC>NCT01610778</DOC>
	<brief_summary>This study is designed to evaluate efficacy of 5-aminolevulinic acid in subjects with type 2 diabetes on medication.</brief_summary>
	<brief_title>Effects of 5-Aminolevulinic Acid on Glucose Metabolism</brief_title>
	<detailed_description />
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>Type 2 diabetic patients on medication HbA1c ≤ 9.0% (as JDS values, which is equivalent to HbA1c ≤ 9.4% as NGSP values) On stable treatment of diabetes for at least the last 3 months With permission to attend the clinical trial from the primary doctor On insulin therapy BMI ≤ 18 kg/m2 or ≥ 30 kg/m2 History of porphyria, hemochromatosis, or viral hepatitis Pregnant or nursing a child Heart disease Renal or hepatic dysfunction Participation in any clinical trial within 90 days of the commencement of the trial</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>